NASDAQ:FENC Adherex Technologies (FENC) Stock Price, News & Analysis $10.68 +0.10 (+0.95%) As of 01:53 PM Eastern This is a fair market value price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsInsider TradesNews and TrendsOptions ChainSEC FilingsShort Interest About Adherex Technologies Stock (NASDAQ:FENC) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Adherex Technologies alerts:Sign Up Key Stats Today's Range$10.45▼$10.7950-Day Range$9.39▼$12.5552-Week Range$5.65▼$13.25Volume114,951 shsAverage Volume198,732 shsMarket Capitalization$376.45 millionP/E RatioN/ADividend YieldN/APrice Target$17.00Consensus RatingModerate Buy Company Overview Fennec Pharmaceuticals, Inc., formerly known as Adherex Technologies, is a biopharmaceutical company focused on developing and commercializing therapies for pediatric cancer. The company’s lead product is PEDMARK (sodium thiosulfate), a platinum-based chemotherapy protective agent intended to reduce the risk of cisplatin-induced ototoxicity, or hearing loss, in children with localized, non-metastatic solid tumors. PEDMARK received approval from the U.S. Food and Drug Administration in 2022. Fennec markets the product in the United States through its commercial operations and has pursued regulatory and commercialization opportunities in international markets. The therapy is administered after cisplatin treatment and is designed to protect hearing without compromising cisplatin’s effectiveness against cancer. The company was originally established as Adherex Technologies and later changed its name to Fennec Pharmaceuticals as its strategy became centered on pediatric oncology. Fennec is headquartered in Research Triangle Park, North Carolina, and its business is primarily focused on supporting the availability and adoption of PEDMARK, while evaluating opportunities to expand its pediatric cancer portfolio.AI Generated. May Contain Errors. Read More Adherex Technologies Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks86th Percentile Overall ScoreFENC MarketRank™: 4.282343688555 of 5 starsAdherex Technologies scored higher than 86% of companies evaluated by MarketBeat, and ranked 66th out of 897 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.7 / 5Analyst RatingModerate Buy Consensus RatingAdherex Technologies has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on no strong buy ratings, 4 buy ratings, 1 hold rating, and 1 sell rating.Upside PotentialAdherex Technologies has a consensus price target of $17.00, representing about 60.2% upside from its current price of $10.62.Amount of Analyst CoverageAdherex Technologies has only been the subject of 2 research reports in the past 90 days.Read more about Adherex Technologies' stock forecast and price target. Earnings and Valuation1.9 / 5Proj. Earnings Growth246.43% Earnings GrowthEarnings for Adherex Technologies are expected to grow by 246.43% in the coming year, from $0.28 to $0.97 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Adherex Technologies is -82.04, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Adherex Technologies is -82.04, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioAdherex Technologies has a P/B Ratio of 10.21. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Adherex Technologies' valuation and earnings. Short Interest5.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted1.45% of the float of Adherex Technologies has been sold short.Short Interest Ratio / Days to CoverAdherex Technologies has a short interest ratio ("days to cover") of 3.89, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Adherex Technologies has recently decreased by 6.78%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldAdherex Technologies does not currently pay a dividend.Dividend GrowthAdherex Technologies does not have a long track record of dividend growth. News and Social Media2.8 / 5News Sentiment0.46 News SentimentAdherex Technologies has a news sentiment score of 0.46. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.57 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 5 news articles for Adherex Technologies this week, compared to 2 articles on an average week.Search Interest1 people have searched for FENC on MarketBeat in the last 30 days. Company Ownership1.8 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Adherex Technologies insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $1,029,660.00 in company stock.Percentage Held by Insiders10.73% of the stock of Adherex Technologies is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions55.51% of the stock of Adherex Technologies is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Adherex Technologies' insider trading history. Receive FENC Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Adherex Technologies and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. FENC Stock News HeadlinesFennec Pharmaceuticals to Report Third Quarter 2026 Financial Results on November 12, 2026November 6, 2026 | globenewswire.comAdherex Technologies (FENC) Set to Release Quarterly Earnings on ThursdayNovember 5, 2026 | americanbankingnews.comA free stock pick, from me to youElon's paid this chip supplier since 2012. When NVIDIA tried to buy the company, he fought the deal. Without its chip, his AI satellites don't fly. Now he wants 1,000,000 of them in orbit, 100 times what's up there today, and every one pays this company a royalty. Dylan believes shares could react by December 8th.November 11 at 1:00 AM | Behind the Markets (Ad)Fennec Pharmaceuticals Announces Oral Presentation of Detailed Results from Investigator-Initiated Phase 2 STS-J01 Clinical Study of Pedmark® in Japan at SIOP 2026September 17, 2026 | globenewswire.comFennec Pharmaceuticals to Report Second Quarter 2026 Financial Results on August 11, 2026August 5, 2026 | globenewswire.comFennec Announces Results of Annual MeetingJune 10, 2026 | globenewswire.comAdherex Technologies' PEDMARK push targets larger AYA market after record quarterMay 23, 2026 | msn.comFennec Pharmaceuticals Announces New Research Supporting Integration and Use of PEDMARK® at the 2026 ASCO Annual MeetingMay 21, 2026 | globenewswire.comSee More Headlines FENC Stock Analysis - Frequently Asked Questions How have FENC shares performed this year? Adherex Technologies' stock was trading at $7.70 on January 1st, 2026. Since then, FENC shares have increased by 37.9% and is now trading at $10.6150. How were Adherex Technologies' earnings last quarter? Adherex Technologies Inc. (NASDAQ:FENC) posted its earnings results on Thursday, August, 13th. The company reported $0.05 EPS for the quarter, topping analysts' consensus estimates of $0.02 by $0.03. The firm had revenue of $17.87 million for the quarter, compared to analysts' expectations of $16.21 million. Adherex Technologies had a negative net margin of 6.09% and a negative trailing twelve-month return on equity of 5.71%. Read the conference call transcript. How do I buy shares of Adherex Technologies? Shares of FENC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Adherex Technologies own? Based on aggregate information from My MarketBeat watchlists, some other companies that Adherex Technologies investors own include NVIDIA (NVDA), Ocular Therapeutix (OCUL), Gilead Sciences (GILD), Iovance Biotherapeutics (IOVA), Pfizer (PFE), ExxonMobil (XOM) and Moderna (MRNA). Company Calendar Last Earnings8/13/2026Today11/11/2026Next Earnings (Estimated)11/12/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (5d) 1-Year History Nov 25 Feb 26 May 26 Aug 26 Nov 26 As of 5 days ago, FENC's financial health entered the Green zone, according to TradeSmith. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Pharmaceuticals Sub-IndustryPharmaceuticals Current SymbolNASDAQ:FENC CIK1211583 Webwww.fennecpharma.com Phone919-636-4530Fax919-890-0490Employees35Year Founded1996Price Target and Rating Average Price Target for Adherex Technologies$17.00 High Price Target$18.00 Low Price Target$16.00 Potential Upside/Downside+60.1%Consensus RatingModerate Buy Rating Score (0-4)2.50 Research Coverage6 Analysts Profitability EPS (Trailing Twelve Months)($0.13) Trailing P/E RatioN/A Forward P/E Ratio10.95 P/E GrowthN/ANet Income-$9.74 million Net Margins-6.09% Pretax Margin-5.24% Return on Equity-5.71% Return on Assets-2.37% Debt Debt-to-Equity RatioN/A Current Ratio5.85 Quick Ratio5.66 Sales & Book Value Annual Sales$59.22 million Price / Sales6.32 Cash FlowN/A Price / Cash FlowN/A Book Value$1.04 per share Price / Book10.21Miscellaneous Outstanding Shares35,215,000Free Float31,436,000Market Cap$373.98 million OptionableOptionable Beta1.29 7 Energy Stocks to Buy and Hold ForeverOil still powers the global economy, but AI is reshaping the energy opportunity. Discover seven stocks spanning traditional energy, infrastructure, and next-generation power.Get This Free Report This page (NASDAQ:FENC) was last updated on 11/11/2026 by MarketBeat.com Staff. From Our PartnersWhy I'm selling my Snapback Indicator for just $7For Black Friday, Base Camp Trading's Thomas Wood is offering lifetime access to his proprietary Snapback Indi...Base Camp Trading | SponsoredTrump’s EO to send this $5 stock ripping higher…?President Trump's December executive order declared space a national security and economic priority, fueling a...Traders Agency | SponsoredThe Withdrawal You'll Never See on Your StatementA proposal circulating in Washington, dubbed the Mar-a-Lago Accord, calls for tariffs and currency pressure to...Bishop Gold Group | SponsoredToday's free pick (on me)Elon Musk doesn't own the chip inside every Tesla, Starlink dish, and AI satellite - he licenses it from one l...Behind the Markets | SponsoredDrop these 5 stocks before the market opens tomorrow!The Wall Street Journal called it the "$64 trillion question": is a stock market crash on the way? Weiss Ratin...Weiss Ratings | SponsoredYour free book is about to disappearBill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...Profits Run | SponsoredThe investigation Porter spent tens of thousands to documentPorter Stansberry flew the Porter and Co. team 3,300 miles to Dublin to investigate a 17-year investing experi...Porter & Company | SponsoredUranium Mine Flood That Sparked a 2006 Price Surge ReturnsIn 2006, a flooded mine at Cigar Lake sent uranium prices from the $50 range to $136 in eight months. This pa...Digest Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Adherex Technologies Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Adherex Technologies With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
